Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction

Ahnve, Staffan

doi:10.1016/0002-8703(85)90564-2

Cited by 303 publications

(125 citation statements)

References 56 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Six methods have been proposed, 84,85 and a recent article by experts in the field has suggested normal QTc values. A Bazett-corrected QT interval Ͼ460 ms on ECG was stated to be prolonged in a study of 158 children.…”

Section: Measurement Of the Qt Interval And Predictive Valuementioning

confidence: 99%

Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder

Vetter¹,

Elia²,

Erickson³

et al. 2008

Circulation

260

View full text Add to dashboard Cite

Section: Measurement Of the Qt Interval And Predictive Valuementioning

confidence: 99%

Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder

Vetter¹,

Elia²,

Erickson³

et al. 2008

Circulation

260

View full text Add to dashboard Cite

“…40,41 The most widely used is the formula derived by Bazett 42 in 1920 from a graphic plot of measured QT intervals in 39 young subjects. This adjustment procedure divides the measured QT by the square root of the RR interval to derive the rate-adjusted value.…”

Section: Qt Correction For Ratementioning

confidence: 99%

AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram

Rautaharju¹,

Surawicz²,

Gettes³

2009

Circulation

380

222

View full text Add to dashboard Cite

“…Bazett, Fridericia, Framingham, etc.) [64,65] . While these formulae are appropriate in standard clinical practice, e.g.…”

Section: Phase I/ii Studiesmentioning

confidence: 99%

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology

Haverkamp¹,

Breithardt²,

Janse³

et al. 2000

European Heart Journal

409

273

View full text Add to dashboard Cite

The scientific and clinical basis of drug-induced QT prolongation and proarrhythmia was summarized by formal presentations. The speakers were chosen for their particular competence in the relevant field. Furthermore, selected topics were discussed in detail in separate workshops. This document represents the executive summary of the Conference. It is based on written reports composed by the speakers and the chairs of the workshops. Before preparation of the final version of the document, a draft was circulated to all participants of the Conference for suggestions and comments. The opinions expressed in this document are those of the participants and do not necessarily reflect the official position of their organisations or agencies. The meeting was made possible by unrestricted educational grants to the Committee for Scientific and Clinical Initiatives of the ESC from several companies listed in the Appendix. The problemQT interval prolongation, and possibly increased QT dispersion, are risk factors in a number of cardiovascular as well as non-cardiovascular diseases. A variety of drugs prolong the QT interval, although the major examples are the so-called class III antiarrhythmics. These drugs generally exert their therapeutic effect by affecting potassium ion channels, thereby reducing outward, repolarizing current, and prolonging action potential duration and the QT interval. Many of these drugs have been developed for conversion of atrial fibrillation and/or maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Such patients are at low risk of potentially fatal arrhythmias, at least in the absence of antiarrhythmic drug therapy.However, antiarrhythmic drugs which prolong cardiac repolarization are not harmless, as they may induce

show abstract

Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction

Cited by 303 publications

References 56 publications

Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder

Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder

AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology

Contact Info

Product

Resources

About